Zanubrutinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 595 publications
Successful treatment with zanubrutinib for Bing-Neel syndrome progressing on ibrutinib: a case report and literature review.
Journal: Leukemia & lymphoma
Published: April 08, 2026
Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders.
Journal: Pharmacological research
Published: March 31, 2026
Precision targeting of BTK in chronic lymphocytic leukemia: computational insights into structural dynamics and the influence of mutations on BTK inhibitors through QM and MM studies.
Journal: Journal of biomolecular structure & dynamics
Published: March 23, 2026
CAR-T cell therapy bridging to allogeneic hematopoietic stem cell transplantation for diffuse large B-cell Richter syndrome: a case report and literature review
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 16, 2026
Efficacy and safety analysis of BTK inhibitors combined with R-CHOP regimen in newly diagnosed double-expressor diffuse large B-cell lymphoma
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 16, 2026
Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysis.
Journal: Leukemia & lymphoma
Published: March 07, 2026
Skin toxicities related to Bruton tyrosine kinase inhibitors: an updated review.
Journal: Expert review of clinical immunology
Published: February 19, 2026
Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial.
Journal: Current medical research and opinion
Published: February 13, 2026
Correction: Case Report: renal allograft infiltration by chronic lymphocytic leukemia successfully treated with zanubrutinib.
Journal: Frontiers in oncology
Published: February 12, 2026
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia.
Journal: Expert review of hematology
Published: February 10, 2026
Involvement of Btk in Cardiovascular Disease and Its Therapeutic Targeting.
Journal: Circulation
Published: February 09, 2026
Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma.
Journal: Expert review of hematology
Published: February 09, 2026
Last Updated: 04/28/2026